Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

• Published in: PloS one 2017-07, Vol.12 (7), p.e0179431
• Main Authors: Charych, Deborah, Khalili, Samira, Dixit, Vidula, Kirk, Peter, Chang, Thomas, Langowski, John, Rubas, Werner, Doberstein, Stephen K, Eldon, Michael, Hoch, Ute, Zalevsky, Jonathan
• Format: Article
• Language: English
• Subjects: Affinity; Algorithms; Animals; Anticancer properties; Biological effects; Biology and Life Sciences; Cancer; Cancer immunotherapy; Cancer treatment; CD8 antigen; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - metabolism; Cell activation; Cell Line, Tumor; Conjugates; Cytokines; Drug dosages; Drug Liberation; Female; Immune system; Immunology; Immunoregulation; Immunotherapy; Immunotherapy - methods; In vitro methods and tests; Interleukin; Interleukin 2; Interleukin 2 receptors; Interleukin Receptor Common gamma Subunit - agonists; Interleukin Receptor Common gamma Subunit - metabolism; Interleukin-2 - analogs & derivatives; Interleukin-2 - pharmacokinetics; Interleukin-2 - pharmacology; Interleukin-2 Receptor alpha Subunit - agonists; Interleukin-2 Receptor alpha Subunit - metabolism; Interleukin-2 Receptor beta Subunit - agonists; Interleukin-2 Receptor beta Subunit - metabolism; Kinetics; Ligands; Lymphocytes; Lymphocytes T; Medicine and Health Sciences; Melanoma; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Modelling; Models, Theoretical; Mutation; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - therapy; Patient outcomes; Pharmacodynamics; Pharmacokinetics; Pharmacology; Phosphorylation - drug effects; Physical Sciences; Physiological aspects; Polyethylene glycol; Polyethylene Glycols - pharmacokinetics; Polyethylene Glycols - pharmacology; Polyethylenes; Prodrugs - pharmacokinetics; Prodrugs - pharmacology; Proteins; Receptors, Interleukin-2 - agonists; Receptors, Interleukin-2 - metabolism; STAT5 Transcription Factor - metabolism; T-Lymphocytes, Regulatory - drug effects; T-Lymphocytes, Regulatory - immunology; T-Lymphocytes, Regulatory - metabolism; Transplantation, Homologous; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0179431

Cytokines are potent immune modulating agents but are not ideal medicines in their natural form due to their short half-life and pleiotropic systemic effects. NKTR-214 is a clinical-stage biologic that comprises interleukin-2 (IL2) protein bound by multiple releasable polyethylene glycol (PEG) chains. In this highly PEG-bound form, the IL2 is inactive; therefore, NKTR-214 is a biologic prodrug. When administered in vivo, the PEG chains slowly release, creating a cascade of increasingly active IL2 protein conjugates bound by fewer PEG chains. The 1-PEG-IL2 and 2-PEG-IL2 species derived from NKTR-214 are the most active conjugated-IL2 species. Free-IL2 protein is undetectable in vivo as it is eliminated faster than formed. The PEG chains on NKTR-214 are located at the region of IL2 that contacts the alpha (α) subunit of the heterotrimeric IL2 receptor complex, IL2Rαβγ, reducing its ability to bind and activate the heterotrimer. The IL2Rαβγ complex is constitutively expressed on regulatory T cells (Tregs). Therefore, without the use of mutations, PEGylation reduces the affinity for IL2Rαβγ to a greater extent than for IL2Rβγ, the receptor complex predominant on CD8 T cells. NKTR-214 treatment in vivo favors activation of CD8 T cells over Tregs in the tumor microenvironment to provide anti-tumor efficacy in multiple syngeneic models. Mechanistic modeling based on in vitro and in vivo kinetic data provides insight into the mechanism of NKTR-214 pharmacology. The model reveals that conjugated-IL2 protein derived from NKTR-214 occupy IL-2Rβγ to a greater extent compared to free-IL2 protein. The model accurately describes the sustained in vivo signaling observed after a single dose of NKTR-214 and explains how the properties of NKTR-214 impart a unique kinetically-controlled immunological mechanism of action.